GlassScriptPhysician profile
Timothy T Tang
NPI 1093805046
$2,043.68
in general payments reported to CMS, 2019-2025
22 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $477 · 2021: $506 · 2022: $154 · 2023: $179 · 2024: $273 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $479.06 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $299.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $175.67 | 2020-2025 | |
| Exact Sciences Corporation | $167.95 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $164.44 | 2019-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $138.88 | 2019-2022 | |
| Allergan, INC. | $97.78 | 2019-2020 | |
| Amgen INC. | $66.40 | 2019-2020 | |
| Abbvie INC. | $57.42 | 2021 | |
| Amarin Pharma, INC. | $56.06 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $46.70 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $44.14 | 2022-2023 | Seglentis |
| Abbott Laboratories | $40.09 | 2023-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $34.55 | 2023 | Arexvy, Shingrix |
| Dexcom, INC. | $27.49 | 2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $25.95 | 2019 | |
| Pfizer INC. | $25.00 | 2024 | |
| Medtronic, INC. | $24.49 | 2025 | Venaseal |
| Esperion Therapeutics, INC. | $22.06 | 2020 | |
| Biocryst US Sales Co., LLC | $18.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.95 | 2020 | |
| Merck Sharp & Dohme LLC | $14.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.